EC Number   |
Application |
Reference |
|---|
   2.7.3.9 | drug development |
enzyme I, EI, of the phosphoenolpyruvate phosphotransferase system isa drug target to develop antimicrobial agents, xanthone derivatives have high potential to be developed as antibiotics |
738469 |
| 2.7.3.9 | drug development |
the enzyme is a target for antibacterial drugs. These drugs can be obtained from peptides or protein fragments able to interfere with the first reaction of the protein cascade: the phosphorylation of the HPr by the first enzyme, the so-called enzyme enzyme I, overview |
691334 |
| 2.7.3.9 | medicine |
recombinant enzyme and anti-enzyme antiserum inhibit adhesion of Streptococcus pneumoniae to cultured human lung adenocarcinoma A-549 cells |
-, 762209 |
| 2.7.3.9 | medicine |
the enzyme can function as an adhesin, evaluation of its potential as a vaccine. Immunization with rPtsA protects mice against a sublethal intranasal and a lethal intravenous pneumococcal challenge. PtsA binding peptides derived from its putative target molecules can be considered for development of therapeutics, and rPtsA is a candidate for vaccine development |
739444 |
| 2.7.3.9 | medicine |
virulence of enzyme deletion mutants |
642526 |
